Progenics Pharmaceuticals, Inc. (PGNX) Forms $5.51 Double Bottom; 2 Analysts Are Bullish Johnston Press plc (LON:JPR) Last Week

Progenics Pharmaceuticals, Inc. (PGNX) formed double bottom with $5.34 target or 3.00% below today’s $5.51 share price. Progenics Pharmaceuticals, Inc. (PGNX) has $387.19 million valuation. The stock increased 2.80% or $0.15 during the last trading session, reaching $5.51. About 133,750 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since February 7, 2017 and is uptrending. It has outperformed by 31.71% the S&P500.

Among 5 analysts covering Johnston Press PLC (LON:JPR), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Johnston Press PLC had 57 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of Johnston Press plc (LON:JPR) earned “Sell” rating by Peel Hunt on Wednesday, January 20. Numis Securities maintained the stock with “Equal-Weight” rating in Tuesday, August 11 report. Liberum Capital maintained Johnston Press plc (LON:JPR) rating on Thursday, February 18. Liberum Capital has “Buy” rating and GBX 120 target. The stock of Johnston Press plc (LON:JPR) has “Buy” rating given on Tuesday, August 11 by Panmure Gordon. The rating was maintained by Liberum Capital on Wednesday, May 18 with “Buy”. Liberum Capital maintained it with “Buy” rating and GBX 80 target in Wednesday, August 2 report. The firm earned “Buy” rating on Monday, January 15 by Liberum Capital. The stock has “Buy” rating by Panmure Gordon on Wednesday, October 26. The stock of Johnston Press plc (LON:JPR) has “Buy” rating given on Wednesday, February 3 by Panmure Gordon. Liberum Capital maintained it with “Buy” rating and GBX 80 target in Wednesday, December 6 report. See Johnston Press plc (LON:JPR) latest ratings:

01/02/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 80.00 New Target: GBX 80.00 Maintain
15/01/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 80.00 New Target: GBX 80.00 Maintain
06/12/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 80.00 New Target: GBX 80.00 Maintain
02/11/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 80.00 New Target: GBX 80.00 Maintain
09/10/2017 Broker: Liberum Capital Rating: Buy Old Target: GBX 80.00 New Target: GBX 80.00 Maintain

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. Brean Capital maintained the stock with “Buy” rating in Thursday, August 6 report. Needham maintained Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) on Tuesday, June 20 with “Buy” rating. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Friday, August 7 by Zacks. The rating was maintained by Needham with “Buy” on Friday, August 7. The stock has “Buy” rating by Aegis Capital on Thursday, October 27. The firm has “Buy” rating given on Wednesday, August 9 by Cantor Fitzgerald. The rating was upgraded by Needham on Monday, February 6 to “Strong Buy”. Jefferies upgraded the stock to “Buy” rating in Friday, October 23 report. As per Thursday, June 8, the company rating was maintained by Jefferies. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Tuesday, September 26 by Jefferies.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on March, 8. They expect $-0.21 earnings per share, down 110.00% or $0.11 from last year’s $-0.1 per share. After $-0.22 actual earnings per share reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -4.55% EPS growth.

Investors sentiment decreased to 1.11 in 2017 Q3. Its down 0.18, from 1.29 in 2017Q2. It turned negative, as 22 investors sold Progenics Pharmaceuticals, Inc. shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 58.90 million shares or 4.84% less from 61.90 million shares in 2017Q2 were reported. Opus Point Prtnrs Ltd holds 0.14% or 21,782 shares. Westwood Mngmt Il invested 0.01% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Mark Sheptoff Fincl Planning Ltd Co holds 10 shares or 0% of its portfolio. Louisiana State Employees Retirement Systems has invested 0.01% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Moreover, Aperio Gp Limited Company has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Ls Advsr Lc has 0.01% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 22,806 shares. Gotham Asset Management Ltd reported 33,737 shares stake. Lpl Limited Liability Corp stated it has 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Northern Corp accumulated 0% or 886,616 shares. Tennessee-based State Of Tennessee Treasury Department has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Dekabank Deutsche Girozentrale invested in 0% or 9,000 shares. California State Teachers Retirement Systems reported 113,049 shares or 0% of all its holdings. Barclays Public Ltd Com reported 86,500 shares. Duncker Streett And Communication Incorporated stated it has 14,718 shares or 0.03% of all its holdings. State Street has 3.32 million shares for 0% of their portfolio.